UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): March 1626, 2009

Noven Pharmaceuticals, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)


Delaware	0-17254	59-2767632
_____________________ (State or other jurisdiction	_____________ (Commission	______________ (I.R.S. Employer
of incorporation)	File Number)	Identification No.)

11960 S.W. 144th Street, Miami, Florida		33186
_________________________________ (Address of principal executive offices)		___________ (Zip Code)


Registrant’s telephone number, including area code:		305-253-5099

Not Applicable
______________________________________________
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Top of the Form

Item 81.0102 ~~Other~~Termination ~~Events~~of a Material Definitive Agreement.

As required by Item 1.02 of Form 8-K, Noven Pharmaceuticals, Inc. ("Noven") ~~today~~hereby ~~confirmed~~reports ~~that~~the ~~Shire~~termination ~~plc~~of its Industrial Lease agreement ("~~Shire~~Industrial Lease"), ~~the~~with ~~global~~sanofi-aventis ~~licensee~~(f/k/a ofRhone-Poulenc ~~Daytrana®~~Rorer ~~(methylphenidate~~Pharmaceuticals ~~transdermal~~Inc., ~~system~~"sanofi-aventis") effective as of March 26, ~~has~~2009 ~~announced~~as ~~its~~a ~~withdrawal~~result of ~~the~~Noven's ~~European~~exercise ~~Marketing~~of ~~Authorization~~its ~~Application~~option ~~("MAA")~~under ~~for~~the ~~Daytrana~~Industrial ~~for~~Lease to purchase the ~~treatment~~manufacturing offacility ~~Attention~~and ~~Deficit~~associated ~~Hyperactivity~~real ~~Disorder~~property (the "~~ADHD~~Property")~~. Shire~~ ~~stated~~ that ~~its~~Noven ~~decision~~previously toleased ~~withdraw~~from sanofi-aventis.Under the ~~MAA~~Industrial ~~was~~Lease, ~~based~~dated onMarch ~~the~~23, ~~fact~~1993, ~~that~~Noven ~~European~~leased ~~regulatory~~7.2 ~~authorities~~acres ~~had~~of ~~requested~~land anand ~~additional~~two ~~clinical~~approximately ~~study~~40,000 ~~for~~square ~~Daytrana~~feet buildings located in aMiami, ~~European~~Florida ~~patient~~adjacent ~~population,~~to ~~and~~other ~~that~~real ~~Shire~~property ~~planned~~and tofacilities ~~enter~~owned ~~the~~by ~~European~~Noven. The ~~ADHD~~Industrial ~~market~~Lease ~~through~~provided Noven with the ~~previously-announced~~option ~~pending~~to ~~acquisition~~purchase ofthe anProperty ~~oral~~for ~~methylphenidate~~sanofi-aventis' ~~product~~book ~~that~~value isor ~~already~~$1.00 ~~approved~~when inthe ~~Europe~~Property was fully depreciated. On March 26, 2009, Noven ~~further~~purchased ~~confirmed~~the ~~that~~property ~~its~~from ~~2009~~sanofi-aventis ~~financial~~for ~~guidance~~$1.00. In inconnection with Noven's exercise of its ~~Annual~~purchase ~~Report~~option, onNoven ~~Form~~and 10sanofi-K,aventis ~~dated~~mutually ~~March~~agreed ~~13,~~to ~~2009~~terminate ~~did~~the Industrial Lease. Noven does not ~~include~~expect ~~any~~to ~~revenues~~incur orany ~~other~~material ~~financial~~additional ~~contribution~~expenses ~~from~~as ~~European~~the ~~sales~~owner of ~~Daytrana~~the Property.

Top of the Form

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Noven Pharmaceuticals, Inc.
March 16, 2009	By:	/s/ Jeff Mihm
March 31, 2009	By:	/s/ Jeff Mihm
		Name: Jeff Mihm
		Title: Vice President, General Counsel and Corporate Secretary

Filing Compare · NOVEN PHARMACEUTICALS INC